Key result
The everolimus-eluting bioresorbable vascular scaffold demonstrated 99.2% procedural success and a 6-month target lesion failure rate of 5.6% in a real-world registry of 108 patients.
Observational (n=108)
No
In a real-world registry, the everolimus-eluting bioresorbable vascular scaffold demonstrated excellent procedural success and acceptable mid-term clinical outcomes, with scaffold thrombosis rates comparable to other registries.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; hypothesis-generating for bioresorbable scaffolds pending randomized trials.
Data on procedural and clinical outcomes of the everolimus-eluting bioresorbable vascular scaffold (BVS, Abbott) in percutaneous coronary intervention in a real-world setting is limited. Early and mid-term clinical outcomes of the BVS in a real-world population were investigated in this single centre study. Patients treated with the BVS in the St. Antonius Hospital from April 2012 to February 2015 were included in a prospective single centre registry. Procedural success defined as < 20% residual restenosis and 30-day and 6-month clinical outcome were investigated. Cumulative event rates were expressed using Kaplan − Meier method. A total of 108 patients were included in the study, including patients with ST-segment elevation myocardial infarction (STEMI) 18.5%, non-STEMI 22.2% and unstable angina 9.3%. In total 125 lesions were treated with the BVS, of which 48.8% B2/C type lesions including 19.2% bare metal or drugs-eluting in-stent restenosis. Procedural angiographic success was achieved in 99.2% of all patients. Clinical follow-up rate was 100% at 30-day and 87% at 6-month. The rate of cardiac death, target vessel revascularization and definite stent thrombosis was 0%, 0.9% and 0.9% at 30-day and 0.9%, 5.6% and 1.9% at 6-month. The composite end point of target lesion failure (Cardiac death, target lesion myocardial infarction MI and target lesion revascularization) was 1.9% at 30-day and 5.6% at 6-month, respectively. The use of the BVS in a real-world setting demonstrated excellent procedural success and acceptable mid-term clinical outcomes. The rate of definite scaffold thrombosis was not dissimilar to other BVS registries.
No takes yet. Share an insight, caveat, or question.
Teeuwen et al. (2015) conducted an observational in Coronary artery disease requiring percutaneous coronary intervention (n=108). Absorb everolimus-eluting bioresorbable vascular scaffold (BVS) was evaluated on Composite end point of target lesion failure (cardiac death, target lesion myocardial infarction, and target lesion revascularization) at 6 months. The everolimus-eluting bioresorbable vascular scaffold demonstrated 99.2% procedural success and a 6-month target lesion failure rate of 5.6% in a real-world registry of 108 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: